Takeda Pharmaceutical Company Limited

Dyax Corporation

Ryan Faucette

Daniel J Sexton

Burt Adelman

Christopher TenHoor

Jon A Kenniston

Malini Viswanathan

Tripti Gaur

Andrew Nixon

Gregory P Conley

Yung Chyung

Guodong Zhang

Jiang Wu

Ryan Iarrobino

Mark Szewc

Gul M Mustafa

Joseph Biedenkapp

Janja Cosic

Greg Conley

Christopher Tenhoor

Methods and assays for determining the activation level of the plasma kallikrein (pKal) system and the uses thereof for assessing the activity of pKal modulators on the pKal system.

Assays for determining plasma kallikrein system biomarkers

Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.

Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema

Provided herein are methods and kits for analyzing a biological sample obtained from a subject having, suspected of having, or being at risk for a disease associated with the contact activation system.

Metabolite biomarkers for diseases associated with the contact activation system

Methods for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK in a sample are provided herein. Such methods may comprise treating a biological sample with a protease to generate a plurality of digested peptides, and measuring one or more signature peptides, which are indicative of cleaved HMWK and/or full-length HMWK.

Peptide quantitation assay for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK

RNA biomarkers for hereditary angioedema

Disclosed herein are evacuated blood collection tubes comprising protease inhibitor cocktails in liquid form and uses thereof for assessing features associated with the contact system in a subject, including the endogenous level of contact system activation, the endogenous level of a drug that targets a component of contact system during treatment, and/or the immunogenicity of such a drug.

Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation

Protein biomarkers for diseases associated with the contact activation system

The present disclosure provides methods of evaluating a subject, e.g., a subject at risk for or suffering from a pKal-mediated or bradykinin-mediated disorder, based on values (e.g., percentages) of intact and/or cleaved kininogen in a sample of the subject. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment. Such methods can involve the use of a detection agent that preferentially binds cleaved kininogen or intact kininogen.

Methods of determining levels of cleaved and/or intact kininogen

The present disclosure provides immunoassay methods of detecting a cleaved high molecular weight kininogen (HMWK) with high sensitivity and specificity and isolated antibodies that specifically bind cleaved HMWK.

Immunoassay to detect cleaved high molecular weight kininogen

Growing community of inventors

Melrose, MA, United States of America

Ryan Faucette